Spanish plasma-derived medicines company Grifols announced that it has successfully completed the refinancing of its 2027 debt maturities through a new credit agreement structured as a Term Loan B ...
Spanish plasma medicines producer Grifols is clapping back at Gotham City Research, filing a lawsuit that accuses the New York hedge fund of “knowingly making false and misleading statements” about ...
Yahoo Finance UK: Assessing Grifols (BME:GRF) Valuation After Recent Share Price Weakness And Perceived Discount
Recent performance context for Grifols Grifols (BME:GRF) has drawn investor attention after a mixed run, with a modest 1 day gain, a negative move over the past week and month, and a deeper decline ...
Assessing Grifols (BME:GRF) Valuation After Recent Share Price Weakness And Perceived Discount
The Globe and Mail: Grifols Refinances 2027 Debt and Extends Maturities with Multi-Billion Term Loan B Package
Detailed price information for Grifols S.A. ADR (GRFS-Q) from The Globe and Mail including charting and trades.
Grifols Refinances 2027 Debt and Extends Maturities with Multi-Billion Term Loan B Package
The Corner: Grifols plans to make early repayment of €500 million of its 7.5% secured bonds maturing in 2030
Link Securities | Grifols (GRF) plans to make an early repayment of €500 million of its 7.5% senior secured bonds maturing in 2030. This transaction would ...
Grifols plans to make early repayment of €500 million of its 7.5% secured bonds maturing in 2030
Seeking Alpha: Grifols: Upside After A Smashing Q1 2023 - I Say 'Buy'
My first take on Grifols, S.A. (GRFS) was poorly timed. The company declined immediately after my piece, and my initial stake went down a bit. I did, however, buy some more, and this balancing of ...